By contrast, more recent in vivo results in a disseminated xenograft model of lymphoblastic leukemia of FT819 (an anti-CD19 CAR-T-cell product derived from a clonal engineered iPSC line by insertion of genes encoding for novel 1XX CAR into the TRAC locus) showed enhanced clearance of tumor as compared with that in control anti-CD19 cells (67). The gene discussed is CD19; the disease is neoplasm.